Omnicell (OMCL)
NASDAQ:OMCL
Want to see OMCL full AI Analyst Report?
Top Page
Omnicell
(NASDAQ:OMCL)
Select Model
Select Model
Rating:66Neutral
Price Target:
$49.00
▲(28.00% Upside)
Action:ReiteratedDate:04/29/26
The score is driven primarily by improving financial health (meaningfully lower leverage and strong free cash flow) and a positive earnings update with raised FY profitability guidance. This is tempered by still-thin current profitability/ROE and a relatively high P/E, while technicals remain bullish but appear overextended (high RSI).
Positive Factors
Stronger balance sheet and lower leverage
Omnicell materially reduced leverage by repaying $175M of debt and maintains sizable equity relative to assets. A cleaner capital structure lowers financial risk, increases flexibility for R&D, M&A or buybacks, and reduces interest burden—supporting multi-quarter resilience.
Negative Factors
Very thin net profitability and low ROE
Despite recent progress, Omnicell’s net margin is essentially flat near break-even and ROE remains weak. This indicates limited earnings power relative to capital invested; absent sustained margin expansion, cash generation and shareholder returns may be constrained over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Stronger balance sheet and lower leverage
Omnicell materially reduced leverage by repaying $175M of debt and maintains sizable equity relative to assets. A cleaner capital structure lowers financial risk, increases flexibility for R&D, M&A or buybacks, and reduces interest burden—supporting multi-quarter resilience.
Read all positive factors
Omnicell (OMCL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.96B
Dividend YieldN/A
Average Volume (3M)480.53K
Price to Earnings (P/E)33.3
Beta (1Y)0.48
Revenue Growth7.86%
EPS Growth-2.92%
CountryUS
Employees3,620
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.55
Shares Outstanding45,477,300
10 Day Avg. Volume331,046
30 Day Avg. Volume480,527
Financial Highlights & Ratios
PEG Ratio-12.16
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue1.56
Enterprise Value/Gross Profit3.59
Enterprise Value/Ebitda16.36
Forecast
1Y Price Target
$59.83Price Target Upside56.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.78
Revenue Forecast (FY)$1.24B
Omnicell Business Overview & Revenue Model
Company Description
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to impr...
How the Company Makes Money
Omnicell makes money by selling and supporting a combination of (1) medication management hardware, (2) software, and (3) associated services. A key revenue stream is the sale of automation and dispensing equipment (e.g., automated dispensing cabi...
Omnicell Key Performance Indicators (KPIs)
Any
Gross Profit by Segment
Analyzes profitability across different business segments, highlighting which areas contribute most to the bottom line and where there might be opportunities or challenges.
Analyzes profitability across different business segments, highlighting which areas contribute most to the bottom line and where there might be opportunities or challenges.
Data provided by:
The Fly
The FlyOmnicell Earnings Call Summary
Earnings Call Date:Apr 28, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: robust top-line growth (+15% YoY), outsized improvement in profitability (non-GAAP EBITDA and EPS nearly doubling year-over-year), improved free cash flow, and constructive commercial traction following the Titan XT and OmniSphere launches. Management raised FY profitability guidance while maintaining revenue and bookings targets. Key risks discussed include near-term pacing of Titan XT adoption due to long capital cycles, a $12M tariff headwind, a lower cash balance after debt repayment and buybacks, and some potential quarter-to-quarter margin/revenue variability as expenses are phased throughout the year. On balance, positive execution, raised guidance, and a strong pipeline outweigh the timing and macro/cyclical headwinds.Positive Updates
Top-Line Revenue Growth
Total revenue of $310 million in Q1 FY2026, up 15% year-over-year and finishing at the upper end of prior guidance.
Negative Updates
Lower Cash Balance Versus Prior Year
Cash and cash equivalents declined to $239 million from $387 million a year ago (≈-38%), primarily reflecting the $175 million debt repayment and prior share repurchases, reducing near-term liquidity versus the prior-year level.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-Line Revenue Growth
Total revenue of $310 million in Q1 FY2026, up 15% year-over-year and finishing at the upper end of prior guidance.
Read all positive updates
Company Guidance
Omnicell reiterated and updated its 2026 guidance, giving Q2 revenue of $307–313M (product $174–177M; services $133–136M) with Q2 non‑GAAP EBITDA of $37–42M and non‑GAAP EPS of $0.40–0.48; for full‑year 2026 it maintained product bookings of $510–560M and ARR of $680–700M while guiding total revenue of $1.215–1.255B (product $690–710M; services $525–545M), raised non‑GAAP EBITDA to $153–168M (from $145–165M) and non‑GAAP EPS to $1.80–2.00 (from $1.65–1.85), and disclosed an estimated ~$12M of tariff‑related P&L costs and an assumed non‑GAAP tax rate of ~15%.Omnicell Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.23B | 1.18B | 1.11B | 1.15B | 1.30B | 1.13B |
| Gross Profit | 532.87M | 503.44M | 471.00M | 499.93M | 588.99M | 554.65M |
| EBITDA | 116.82M | 96.28M | 90.09M | 79.98M | 96.85M | 174.44M |
| Net Income | 20.43M | 2.05M | 12.53M | -20.37M | 5.65M | 77.85M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 1.97B | 2.12B | 2.23B | 2.21B | 2.14B |
| Cash, Cash Equivalents and Short-Term Investments | 239.22M | 196.52M | 381.68M | 467.97M | 341.85M | 359.72M |
| Total Debt | 190.56M | 204.34M | 382.55M | 614.09M | 616.74M | 541.01M |
| Total Liabilities | 747.48M | 742.91M | 877.65M | 1.04B | 1.08B | 995.81M |
| Stockholders Equity | 1.26B | 1.23B | 1.24B | 1.19B | 1.13B | 1.15B |
Cash Flow | ||||||
| Free Cash Flow | 111.77M | 86.89M | 151.26M | 139.62M | 17.04M | 202.84M |
| Operating Cash Flow | 155.88M | 127.30M | 187.72M | 181.09M | 77.78M | 231.81M |
| Investing Cash Flow | -60.49M | -60.36M | -52.79M | -55.02M | -58.67M | -412.50M |
| Financing Cash Flow | -219.96M | -218.32M | -235.58M | 23.42M | -20.95M | 47.36M |
Omnicell Technical Analysis
Positive
38.28
Price Trends
36.96
Positive
41.24
Negative
36.30
Positive
Market Momentum
-0.03
Negative
60.90
Neutral
92.08
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Positive. The current price of 38.28 is above the 20-day moving average (MA) of 34.87, above the 50-day MA of 36.96, and above the 200-day MA of 36.30, indicating a bullish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 60.90 is Neutral, neither overbought nor oversold. The STOCH value of 92.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OMCL.
Omnicell Risk Analysis
Omnicell disclosed 33 risk factors in its most recent earnings report. Omnicell reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Omnicell Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $1.96B | 33.30 | 1.64% | ― | 7.86% | -2.92% | |
65 Neutral | $2.61B | -46.73 | -5.69% | ― | 5.25% | 77.07% | |
64 Neutral | $904.62M | -885.94 | -0.15% | ― | 8.75% | 86.34% | |
63 Neutral | $784.50M | 31.72 | 4.84% | ― | 0.57% | 94.69% | |
56 Neutral | $1.07B | -6.16 | -14.24% | ― | -1.54% | 80.61% | |
53 Neutral | $432.13M | -0.85 | -69.22% | ― | -26.56% | -531.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
OMCL
Omnicell
41.42
10.04
31.99%
EVH
Evolent Health
3.75
-6.20
-62.31%
TDOC
Teladoc
6.06
-0.93
-13.30%
TXG
10x Genomics
22.05
13.95
172.22%
GDRX
GoodRx Holdings
2.36
-2.28
-49.14%
CERT
Certara
6.13
-7.16
-53.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.